Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a note issued to investors on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Trading Down 3.4 %

GLMD opened at $1.68 on Friday. The stock’s 50 day simple moving average is $2.40 and its 200-day simple moving average is $3.38. The stock has a market cap of $1.08 million, a PE ratio of -0.10 and a beta of 0.72. Galmed Pharmaceuticals has a 1 year low of $1.65 and a 1 year high of $23.80.

Institutional Trading of Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 76.14% of the company’s stock.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.